Relypsa (Santa Clara, CA) a clinical-stage developer of a therapeutic for hyperkalemia in congestive heart failure patients, closed a $70M Series B financing. Participants include 5AM Ventures, New Leaf Partners, Delphi Ventures and OrbiMed Advisors.